Search Results - "Santin, A."

Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation by Yan, L, Zhou, J, Gao, Y, Ghazal, S, Lu, L, Bellone, S, Yang, Y, Liu, N, Zhao, X, Santin, A D, Taylor, H, Huang, Y

“…The imprinted, developmentally regulated H19 long noncoding RNA has been implicated in the pathogenesis of diverse human cancers, but the underlying mechanisms…”
Get full text

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study by Matulonis, U.A., Shapira-Frommer, R., Santin, A.D., Lisyanskaya, A.S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G.S., Birrer, M., Provencher, D.M., Sehouli, J., Colombo, N., González-Martín, A., Oaknin, A., Ottevanger, P.B., Rudaitis, V., Katchar, K., Wu, H., Keefe, S., Ruman, J., Ledermann, J.A.

“…Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous…”
Get full text

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial by Bardia, A., Messersmith, W.A., Kio, E.A., Berlin, J.D., Vahdat, L., Masters, G.A., Moroose, R., Santin, A.D., Kalinsky, K., Picozzi, V., O'Shaughnessy, J., Gray, J.E., Komiya, T., Lang, J.M., Chang, J.C., Starodub, A., Goldenberg, D.M., Sharkey, R.M., Maliakal, P., Hong, Q., Wegener, W.A., Goswami, T., Ocean, A.J.

“…Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable…”
Get full text

Shift in emergency department utilization by frequent attendees with sickle cell disease during the COVID‐19 pandemic: A multicentre cohort study by Rech, J. S., Cohen, A., Bartolucci, P., Santin, A., Chantalat Auger, C., Affo, L., Le Jeune, S., Arlet, J. B., Boëlle, P. Y., Steichen, O.

“…Summary While the coronavirus disease‐2019 (COVID‐19) might have increased acute episodes in people living with sickle cell disease (SCD), it may also have…”
Get full text

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793) by Bellone, S., Roque, D.M., Siegel, E.R., Buza, N., Hui, P., Bonazzoli, E., Guglielmi, A., Zammataro, L., Nagarkatti, N., Zaidi, S., Lee, J., Silasi, D.-A., Huang, G.S., Andikyan, V., Damast, S., Clark, M., Azodi, M., Schwartz, P.E., Tymon-Rosario, J., Harold, J., Mauricio, D., Zeybek, B., Menderes, G., Altwerger, G., Ratner, E., Alexandrov, L.B., Iwasaki, A., Kong, Y., Song, E., Dong, W., Elvin, J., Choi, J., Santin, A.D.

Get full text

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma by El-Sahwi, K, Bellone, S, Cocco, E, Cargnelutti, M, Casagrande, F, Bellone, M, Abu-Khalaf, M, Buza, N, Tavassoli, F A, Hui, P, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D

“…Background: Uterine serous papillary adenocarcinoma (USPC) is a rare but highly aggressive variant of endometrial cancer. Pertuzumab is a new humanised…”
Get full text

Carcass and meat quality of young Angus steers with different growth potential finished exclusively grass-fed or corn supplemented by Santin Jr, I. A., Lima, H. L., Mateus, K. A., Santos, M. R., Zampar, A., Cucco, D. C.

“…Beef cattle production has a large variety of systems with different performance and technology levels. This study compared young Angus steers carcass and meat…”
Get full text

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy by Bellone, S, Roque, D, Cocco, E, Gasparrini, S, Bortolomai, I, Buza, N, Abu-Khalaf, M, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D

“…Background: We evaluated the expression of CD46, CD55 and CD59 membrane-bound complement-regulatory proteins (mCRPs) in primary uterine serous carcinoma (USC)…”
Get full text

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy by SANTIN, A. D, ZHAN, F, PECORELLI, S, CANE, S, BELLONE, S, PALMIERI, M, THOMAS, M, BURNETT, A, ROMAN, J. J, CANNON, M. J, SHAUGHNESSY, J. JR

“…Uterine serous papillary cancer (USPC) represents a rare but highly aggressive variant of endometrial cancer, the most common gynecologic tumour in women. We…”
Get full text

Preventive treatment of unruptured intracranial aneurysms in adult patients with sickle cell anemia: A cohort study by Dimancea, A, Mattioni, S, Nouet, A, Drir, M, Santin, A, Marrot, B, Shotar, E, Corcy, C, Bottin, L, Sourour, NA, Premat, K, Alamowitch, S, Carpentier, A, Degos, V, Clarençon, F, Lionnet, F, Lenck, S

“…•Intracranial aneurysms are diagnosed in up to 9% of patients with sickle cell anemia, while consensual approaches to treatment of unruptured intracranial…”
Get full text

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 by Santin, A.D., Scheim, D.E., McCullough, P.A., Yagisawa, M., Borody, T.J.

“…In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the…”
Get full text

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer by Tewari, K.S., Vergote, I., Oaknin, A., Alvarez, E., Gaillard, S., Lheureux, S., Rischin, D., Santin, A.D., Feng, M., Mathias, M., Fury, M., Lowy, I., Monk, B.J.

Get full text

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy by Bellone, S, Tassi, R, Betti, M, English, D, Cocco, E, Gasparrini, S, Bortolomai, I, Black, J D, Todeschini, P, Romani, C, Ravaggi, A, Bignotti, E, Bandiera, E, Zanotti, L, Pecorelli, S, Ardighieri, L, Falchetti, M, Donzelli, C, Siegel, E R, Azodi, M, Silasi, D-A, Ratner, E, Schwartz, P E, Rutherford, T J, Santin, A D

“…Background: We studied the genetic fingerprints of ovarian cancer and validated the potential of Mammaglobin b ( SCGB2A1 ), one of the top differentially…”
Get full text

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo by Schwab, C L, Bellone, S, English, D P, Roque, D M, Lopez, S, Cocco, E, Nicoletti, R, Bortolomai, I, Bonazzoli, E, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Santin, A D

“…Background: Uterine serous carcinomas (USCs) are an aggressive form of uterine cancer that may rely on HER2/neu amplification as a driver of proliferation. The…”
Get full text

Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme BRCA by Altwerger, G, Gressel, G.M, Menderes, G, Black, J.D, Nelson, W.K, Litkouhi, B, Santin, A, Schwartz, P.E, Ratner, E.S

Get full text

A single institution’s experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions by Altwerger, G, Gressel, G.M, English, D.P, Nelson, W.K, Menderes, G, Black, J.D, Santin, A, Schwartz, P.E, Ratner, E.S

Get full text

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study by Ledermann, J.A., Shapira-Frommer, R., Santin, A., Lisyanskaya, A.S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G.S., Birrer, M.J., Provencher, D.M., Sehouli, J., Colombo, N., González-Martín, A., Oaknin, A., Ottevanger, P.B., Rudaitis, V., Cristescu, R., Kobie, J., Ruman, J., Matulonis, U.A.

Get full text

Her2 neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab by Todeschini, P, Cocco, E, Bellone, S, Varughese, J, Lin, K, Carrara, L, Guzzo, F, Buza, N, Hui, P, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D

“…Background: We evaluated shedding of epidermal growth factor type II receptor (Her2/neu) extracellular domain (ECD) in primary uterine serous carcinoma (USC)…”
Get full text

Comprehensive Genomic Profiling of Uterine Leiomyosarcomas Identifies Frequent Clinically Relevant Genomic Alterations and Opportunities for Personalized Therapies by Gunderson, Camille C, Santin, A, delPriore, G, Elvin, J.A, Ramkissoon, S, Ali, S.M, McMahon, C, Fabrizio, D, Chalmers, Z, Frampton, G.M, Chmielecki, J, Vergilio, J, Suhn, J, Gay, L, Miller, V.A, Stephens, P.J, Ross, J.S, Moore, K.N

Get full text

“SCULP” study: The benefits of skin graft pellets on the pain of sickle cell leg ulcers (SCLU) by Caboche-Salouhi, P., Le Seac’h, A., Lionnet, F., Santin, A., Mattioni, S., Tamboura, F., Steichen, O., Barbaud, A., Senet, P.

“…BACKGROUNDLeg ulcers associated with major sickle cell disease (SCLU) are a chronic, painful complication, often treated by autologous skin graft. The…”
Get full text